menu

Assessing the Effectiveness of Lp(a) Lowering Therapies in Clinical Trials

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Assessing the Effectiveness of Lp(a) Lowering Therapies in Clinical Trials

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Facebook Comments

Schedule25 Jun 2024